A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive stage small cell lung cancer (ES-SCLC)

BACKGROUND: AT-101 is an oral inhibitor of the anti-apoptotic Bcl proteins (Bcl-2, Bcl-XL, Bcl-W, and Mcl-1) and an inducer of the pro-apoptotic proteins noxa and puma. We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive stage – small cell lung cancer (ES-SCLC). MET...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Baggstrom, Maria Q., Qi, Yingwei, Koczywas, Marianna, Argiris, Athanassios, Johnson, Elizabeth A., Millward, Michael J., Murphy, Sara C., Erlichman, Charles, Rudin, Charles M., Govindan, Ramaswamy
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3180914/
https://ncbi.nlm.nih.gov/pubmed/21918390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31822e2941
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados